Salix swung to a loss in the fourth quarter as the drug maker recorded sharply lower revenue amid a push to clear out inventory ahead of its merger with Valeant.
from WSJ.com: US Business http://ift.tt/18hv2v8
via IFTTT
from WSJ.com: US Business http://ift.tt/18hv2v8
via IFTTT
No comments:
Post a Comment